Summit Therapeutics Valuation
Is SMMT * undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of SMMT * when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate SMMT *'s fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate SMMT *'s fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for SMMT *?
Other financial metrics that can be useful for relative valuation.
What is SMMT *'s n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | US$14.23b |
Key Statistics | |
---|---|
Enterprise Value/Revenue | n/a |
Enterprise Value/EBITDA | -97.6x |
PEG Ratio | n/a |
Price to Book Ratio vs Peers
How does SMMT *'s PB Ratio compare to its peers?
Company | Forward PB | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 17.4x | ||
CYTK Cytokinetics | 61.4x | 43.1% | US$6.7b |
CRSP CRISPR Therapeutics | 2x | 32.0% | US$4.0b |
RVMD Revolution Medicines | 4.9x | 12.8% | US$7.9b |
BNTX BioNTech | 1.4x | -4.9% | US$29.2b |
SMMT * Summit Therapeutics | 73x | n/a | Mex$14.2b |
Price-To-Book vs Peers: SMMT * is expensive based on its Price-To-Book Ratio (73x) compared to the peer average (17.4x).
Price to Earnings Ratio vs Industry
How does SMMT *'s PE Ratio compare vs other companies in the Global Biotechs Industry?
Price-To-Book vs Industry: SMMT * is expensive based on its Price-To-Book Ratio (73x) compared to the Global Biotechs industry average (2.3x).
Price to Book Ratio vs Fair Ratio
What is SMMT *'s PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PB Ratio | 73x |
Fair PB Ratio | n/a |
Price-To-Book vs Fair Ratio: Insufficient data to calculate SMMT *'s Price-To-Book Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
---|---|---|---|---|---|---|---|
Current | Mex$378.00 | Mex$690.94 +82.8% | 26.9% | Mex$867.66 | Mex$433.91 | n/a | 3 |
Sep ’25 | Mex$258.50 | Mex$282.48 +9.3% | 7.4% | Mex$309.82 | Mex$258.63 | n/a | 3 |
Aug ’25 | n/a | Mex$241.83 0% | 2.6% | Mex$248.13 | Mex$235.52 | n/a | 2 |
Jul ’25 | n/a | Mex$240.00 0% | 3.4% | Mex$248.27 | Mex$231.73 | n/a | 2 |
Jun ’25 | n/a | Mex$178.42 0% | 23.8% | Mex$220.91 | Mex$135.94 | n/a | 2 |
Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.